LAMEA PARP Inhibitor Biomarkers Market

LAMEA PARP Inhibitor Biomarkers Market Size, Share & Trends Analysis Report By Product (Kits, and Assays), By Application, By Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing, and Others), By Country and Growth Forecast, 2024 - 2031

Report Id: KBV-22831 Publication Date: May-2024 Number of Pages: 117
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support

Market Report Description

The Latin America, Middle East and Africa PARP Inhibitor Biomarkers Market would witness market growth of 9.9% CAGR during the forecast period (2024-2031).

The Brazil market dominated the LAMEA PARP Inhibitor Biomarkers Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $33.9 Million by 2031. The Argentina market is showcasing a CAGR of 10.8% during (2024 - 2031). Additionally, The UAE market would register a CAGR of 9.5% during (2024 - 2031).

LAMEA PARP Inhibitor Biomarkers Market

biomarker testing, including it, is increasingly integrated into routine clinical practice across oncology care settings. Healthcare providers recognize the importance of biomarker-guided treatment decisions in optimizing patient outcomes and are incorporating biomarker testing into standard care pathways.

Additionally, Clinical laboratories and molecular diagnostic companies are expanding their testing portfolios to include this, offering healthcare providers access to reliable and comprehensive testing services.

With a higher healthcare budget, Saudi Arabia can invest in expanding its healthcare infrastructure, including hospitals, clinics, and diagnostic facilities. This expansion improves access to healthcare services, including biomarker testing for cancer patients. Increased access to healthcare services leads to higher demand for biomarker testing, including PARP inhibitor biomarkers, thereby driving market growth.

Free Valuable Insights: The Worldwide PARP Inhibitor Biomarkers Market is Projected to reach USD 1.6 Billion by 2031, at a CAGR of 8.3%

Based on Product, the market is segmented into Kits, and Assays. Based on Application, the market is segmented into Breast Cancer, Ovarian Cancer, and Others. Based on Services, the market is segmented into BRCA 1 & 2 Testing, HRD Testing, HRR Testing, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now

List of Key Companies Profiled

  • Myriad Genetics, Inc.
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • NeoGenomics Laboratories
  • Qiagen N.V
  • Agilent Technologies, Inc.
  • Merck KGaA
  • Bayer AG
  • AstraZeneca PLC
  • GlaxoSmithKline PLC (GSK)

LAMEA PARP Inhibitor Biomarkers Market Report Segmentation

By Product

  • Kits
  • Assays

By Application

  • Breast Cancer
  • Ovarian Cancer
  • Others

By Services

  • BRCA 1 & 2 Testing
  • HRD Testing
  • HRR Testing
  • Others

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA


Call: +1(646) 600-5072


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo